Palvella Submits NDA for QTORIN™ Rapamycin
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jun 29 2026
0mins
Source: Newsfilter
Palvella Therapeutics Inc's stock fell by 9.70% as it crossed below the 5-day SMA, reflecting a challenging market environment.
The company has submitted the first module of its NDA for QTORIN™ 3.9% rapamycin anhydrous gel to the FDA, marking a significant step toward potential approval. This submission is part of a broader strategy to address the urgent needs of over 30,000 patients in the U.S. with microcystic lymphatic malformations. The Phase 3 SELVA study has shown promising results, indicating the efficacy of QTORIN™ rapamycin, which could enhance the company's market position significantly if approved.
The implications of this submission are substantial, as QTORIN™ could become the first FDA-approved therapy for its target condition, potentially launching commercially in the first half of 2027. This development is crucial for Palvella's growth and market strategy.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy PVLA?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on PVLA
Wall Street analysts forecast PVLA stock price to rise
15 Analyst Rating
15 Buy
0 Hold
0 Sell
Strong Buy
Current: 140.310
Low
133.00
Averages
182.20
High
212.00
Current: 140.310
Low
133.00
Averages
182.20
High
212.00
About PVLA
Palvella Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies to treat patients suffering from serious, rare genetic skin diseases for which there are no FDA-approved therapies. The Company is developing a pipeline of product candidates based on its patented QTORIN platform, with an initial focus on serious, rare genetic skin diseases, many of which are lifelong in nature. Its QTORIN product candidates are developed to accommodate the cargo at high concentrations in order to drive sufficient drug to its target deep in the epidermis and dermis. The Company's lead product candidate, QTORIN 3.9% rapamycin anhydrous gel (QTORIN rapamycin), is being evaluated in the Phase III SELVA clinical trial in microcystic lymphatic malformations and the Phase II TOIVA clinical trial in cutaneous venous malformations.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Palvella Appoints Matt Pauls to Board of Directors
- New Board Member: Palvella Therapeutics has appointed Matt Pauls to its Board of Directors, leveraging his over 25 years of experience in the rare disease biopharmaceutical sector, which is expected to enhance the company's regulatory and commercialization efforts.
- Extensive Industry Experience: Pauls has held executive roles at companies like Savara, Soleno, and Insmed, notably leading the successful commercialization of KEVEYIS® and Macrilen® at Strongbridge Biopharma, showcasing his deep expertise in product launch strategies.
- Strategic Development Opportunity: As Palvella prepares for the potential launch of QTORIN™ rapamycin, Pauls' addition is poised to provide crucial support for the company's pipeline in rare skin diseases and vascular malformations, aiding in achieving market objectives.
- Future Outlook: Pauls expressed strong conviction in Palvella's strategy and is eager to apply his extensive experience to drive rapid growth, particularly in areas lacking FDA-approved treatment options.
See More
Palvella Submits NDA for QTORIN™ Rapamycin
- Rolling NDA Submission Initiated: Palvella Therapeutics has submitted the first module of its NDA for QTORIN™ 3.9% rapamycin anhydrous gel to the FDA, marking a significant step toward potential approval, with plans to complete the remaining modules in the second half of 2026, thereby accelerating treatment for patients with microcystic lymphatic malformations.
- Significant Market Potential: QTORIN™ rapamycin is poised to become the first FDA-approved therapy for microcystic lymphatic malformations, addressing the urgent needs of over 30,000 patients in the U.S., and if approved, is expected to launch commercially in the first half of 2027, significantly enhancing the company's market position.
- Clinical Trial Results Promising: The Phase 3 SELVA study demonstrated highly statistically significant improvements across primary and secondary endpoints, indicating the efficacy and good tolerability of QTORIN™ rapamycin in targeting microcystic lymphatic malformations, laying a solid foundation for future market promotion.
- Strategic Partnerships and Awareness Campaign: Palvella has launched the BEYOND mLM campaign in collaboration with various organizations to raise awareness about microcystic lymphatic malformations, supporting early diagnosis and education, which will further enhance patient and physician acceptance of the new therapy and drive rapid market development.
See More
Palvella COO Sells Stock Options for $476,000
- Stock Option Transaction: Kathleen Goin, COO of Palvella Therapeutics, exercised 4,302 stock options, converting them into common shares for a total transaction value of approximately $476,000, indicating the company's active engagement in the capital markets.
- Ownership Change Analysis: While Goin's direct ownership of common stock has dropped to zero, she retains 17,219 outstanding options, preserving her economic interest in the company, particularly against the backdrop of rising stock prices.
- Market Performance Review: The shares were sold at a weighted average price of around $110.73, while the stock price surged to $148.21 as of June 26, 2026, reflecting nearly a 620% annual increase, showcasing market optimism regarding QTORIN.
- Regulatory Progress and Market Outlook: Palvella recently received FDA rolling review for its New Drug Application for QTORIN, with plans to complete the submission in the second half of 2026, and management aims to leverage Breakthrough Therapy and Fast Track designations to expedite the approval process, enhancing investor confidence in the company's future.
See More
Palvella Therapeutics Executive Exercises Stock Options
- Stock Option Exercise: Kathleen Goin, COO of Palvella Therapeutics, exercised and sold 4,302 common shares on June 17, 2026, for approximately $476,000 at an average price of $110.73 per share, indicating executive confidence in the company's future stock performance.
- FDA Review Progress: The company recently received FDA rolling review for its New Drug Application for QTORIN rapamycin, suggesting a positive regulatory outlook for its rare skin disease treatment, which could expedite the approval process and enhance market competitiveness.
- Strong Market Performance: Palvella's shares have surged nearly 620% over the past year, reflecting investor optimism regarding its lead therapy QTORIN, further solidifying the company's position in the rare disease treatment market.
- Strategic Market Shift: The recent move of Palvella's shares to the Nasdaq Global Market is expected to increase the company's visibility, aiding in garnering more attention and investment for its potential first-in-disease therapies.
See More
Palvella Therapeutics Executive Sells Stock Options for $476,000
- Executive Transaction Overview: Kathleen Goin, COO of Palvella Therapeutics, exercised 4,302 stock options and immediately converted them into common shares for a transaction value of approximately $476,000, indicating proactive management of executive holdings.
- Ownership Change Analysis: While Goin's direct ownership of common stock is now zero, she retains 17,219 outstanding options, preserving her economic interest through potential future share conversions, reflecting confidence in the company's growth trajectory.
- Market Reaction and Stock Performance: The shares were sold at a weighted average price of $110.73, while the stock closed at $148.21 on June 26, 2026, showcasing a nearly 620% increase over the past year, highlighting market optimism surrounding QTORIN.
- Regulatory and Future Outlook: Goin's transaction was executed under a Rule 10b5-1 trading plan adopted on August 19, 2025; despite insider sales, upcoming FDA rolling review and new drug application submission are likely to have a more significant impact on the company's commercialization prospects.
See More
Palvella Receives FDA Rolling Review for Qtorin Application
- FDA Rolling Review: Palvella Therapeutics announced that its new drug application for Qtorin rapamycin has received a rolling review from the FDA, a process designed to expedite the evaluation of drugs for treating microcystic lymphatic malformations, indicating the FDA's recognition of the drug's potential efficacy.
- Therapeutic Potential: Qtorin rapamycin is Palvella's lead candidate, designed to deliver rapamycin directly to pathogenic skin tissue to inhibit disease-driving mTOR signaling, expected to provide a new treatment option for mLM patients who currently have no FDA-approved therapies.
- Clinical Trial Success: In the Phase 3 SELVA trial, Qtorin rapamycin successfully met its primary endpoint, demonstrating its efficacy in treating microcystic lymphatic malformations and laying the groundwork for the upcoming NDA submission.
- Future Plans: Palvella plans to complete the NDA submission in the second half of 2026, further advancing Qtorin's market access, while the drug is also being developed for treating cutaneous venous malformations and clinically significant angiokeratomas, showcasing its broad application potential.
See More
Palvella Appoints Matt Pauls to Board of Directors
- New Board Member: Palvella Therapeutics has appointed Matt Pauls to its Board of Directors, leveraging his over 25 years of experience in the rare disease biopharmaceutical sector, which is expected to enhance the company's regulatory and commercialization efforts.
- Extensive Industry Experience: Pauls has held executive roles at companies like Savara, Soleno, and Insmed, notably leading the successful commercialization of KEVEYIS® and Macrilen® at Strongbridge Biopharma, showcasing his deep expertise in product launch strategies.
- Strategic Development Opportunity: As Palvella prepares for the potential launch of QTORIN™ rapamycin, Pauls' addition is poised to provide crucial support for the company's pipeline in rare skin diseases and vascular malformations, aiding in achieving market objectives.
- Future Outlook: Pauls expressed strong conviction in Palvella's strategy and is eager to apply his extensive experience to drive rapid growth, particularly in areas lacking FDA-approved treatment options.
See More
Palvella Submits NDA for QTORIN™ Rapamycin
- Rolling NDA Submission Initiated: Palvella Therapeutics has submitted the first module of its NDA for QTORIN™ 3.9% rapamycin anhydrous gel to the FDA, marking a significant step toward potential approval, with plans to complete the remaining modules in the second half of 2026, thereby accelerating treatment for patients with microcystic lymphatic malformations.
- Significant Market Potential: QTORIN™ rapamycin is poised to become the first FDA-approved therapy for microcystic lymphatic malformations, addressing the urgent needs of over 30,000 patients in the U.S., and if approved, is expected to launch commercially in the first half of 2027, significantly enhancing the company's market position.
- Clinical Trial Results Promising: The Phase 3 SELVA study demonstrated highly statistically significant improvements across primary and secondary endpoints, indicating the efficacy and good tolerability of QTORIN™ rapamycin in targeting microcystic lymphatic malformations, laying a solid foundation for future market promotion.
- Strategic Partnerships and Awareness Campaign: Palvella has launched the BEYOND mLM campaign in collaboration with various organizations to raise awareness about microcystic lymphatic malformations, supporting early diagnosis and education, which will further enhance patient and physician acceptance of the new therapy and drive rapid market development.
See More
Palvella COO Sells Stock Options for $476,000
- Stock Option Transaction: Kathleen Goin, COO of Palvella Therapeutics, exercised 4,302 stock options, converting them into common shares for a total transaction value of approximately $476,000, indicating the company's active engagement in the capital markets.
- Ownership Change Analysis: While Goin's direct ownership of common stock has dropped to zero, she retains 17,219 outstanding options, preserving her economic interest in the company, particularly against the backdrop of rising stock prices.
- Market Performance Review: The shares were sold at a weighted average price of around $110.73, while the stock price surged to $148.21 as of June 26, 2026, reflecting nearly a 620% annual increase, showcasing market optimism regarding QTORIN.
- Regulatory Progress and Market Outlook: Palvella recently received FDA rolling review for its New Drug Application for QTORIN, with plans to complete the submission in the second half of 2026, and management aims to leverage Breakthrough Therapy and Fast Track designations to expedite the approval process, enhancing investor confidence in the company's future.
See More
Palvella Therapeutics Executive Exercises Stock Options
- Stock Option Exercise: Kathleen Goin, COO of Palvella Therapeutics, exercised and sold 4,302 common shares on June 17, 2026, for approximately $476,000 at an average price of $110.73 per share, indicating executive confidence in the company's future stock performance.
- FDA Review Progress: The company recently received FDA rolling review for its New Drug Application for QTORIN rapamycin, suggesting a positive regulatory outlook for its rare skin disease treatment, which could expedite the approval process and enhance market competitiveness.
- Strong Market Performance: Palvella's shares have surged nearly 620% over the past year, reflecting investor optimism regarding its lead therapy QTORIN, further solidifying the company's position in the rare disease treatment market.
- Strategic Market Shift: The recent move of Palvella's shares to the Nasdaq Global Market is expected to increase the company's visibility, aiding in garnering more attention and investment for its potential first-in-disease therapies.
See More
Palvella Therapeutics Executive Sells Stock Options for $476,000
- Executive Transaction Overview: Kathleen Goin, COO of Palvella Therapeutics, exercised 4,302 stock options and immediately converted them into common shares for a transaction value of approximately $476,000, indicating proactive management of executive holdings.
- Ownership Change Analysis: While Goin's direct ownership of common stock is now zero, she retains 17,219 outstanding options, preserving her economic interest through potential future share conversions, reflecting confidence in the company's growth trajectory.
- Market Reaction and Stock Performance: The shares were sold at a weighted average price of $110.73, while the stock closed at $148.21 on June 26, 2026, showcasing a nearly 620% increase over the past year, highlighting market optimism surrounding QTORIN.
- Regulatory and Future Outlook: Goin's transaction was executed under a Rule 10b5-1 trading plan adopted on August 19, 2025; despite insider sales, upcoming FDA rolling review and new drug application submission are likely to have a more significant impact on the company's commercialization prospects.
See More
Palvella Receives FDA Rolling Review for Qtorin Application
- FDA Rolling Review: Palvella Therapeutics announced that its new drug application for Qtorin rapamycin has received a rolling review from the FDA, a process designed to expedite the evaluation of drugs for treating microcystic lymphatic malformations, indicating the FDA's recognition of the drug's potential efficacy.
- Therapeutic Potential: Qtorin rapamycin is Palvella's lead candidate, designed to deliver rapamycin directly to pathogenic skin tissue to inhibit disease-driving mTOR signaling, expected to provide a new treatment option for mLM patients who currently have no FDA-approved therapies.
- Clinical Trial Success: In the Phase 3 SELVA trial, Qtorin rapamycin successfully met its primary endpoint, demonstrating its efficacy in treating microcystic lymphatic malformations and laying the groundwork for the upcoming NDA submission.
- Future Plans: Palvella plans to complete the NDA submission in the second half of 2026, further advancing Qtorin's market access, while the drug is also being developed for treating cutaneous venous malformations and clinically significant angiokeratomas, showcasing its broad application potential.
See More
